Solvonis Therapeutics PLC (SVNS)

ORD GBP0.001

Sell: 0.25p|Buy: 0.27p|Change: 0 (0%)

Open

0.26p

Previous close

0.26p

Trade high

0.27p

Volume

12,254,059

Year high

0.40p

Year low

0.1095p

Dividend yield

–

Market capitalisation

£17.70 mn

P/E ratio

1.30

ISIN

GB00BMD1Z199

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPPand can be used with Dividend reinvestment

Share price

Performance 13/02/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Solvonis Therapeutics PLC	0.00
More...

Company profile

Solvonis Therapeutics PLC, formerly Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment. The Company operates in two business segments being polymer development and production in Slovenia.

Sector

Industrials

News

Recent trades

Date	Time	Price	Quantity	Value (£)
13/02/2026	04:13:59	0.261	500,000	1,305.00
13/02/2026	02:53:37	0.261	161,153	420.61
13/02/2026	02:03:21	0.261	512,379	1,337.31
13/02/2026	02:00:09	0.2542	1,435	3.65
13/02/2026	02:00:01	0.25	221,435	553.59

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.